Last reviewed · How we verify

Schaper & Bruemmer GmbH & Co KG — Portfolio Competitive Intelligence Brief

Schaper & Bruemmer GmbH & Co KG pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Black Cohosh (iCR) or tibolone Black Cohosh (iCR) or tibolone phase 3 Herbal extract / Selective tissue estrogenic activity regulator (STEAR) Serotonin receptors (Black Cohosh); estrogen receptor, progesterone receptor, androgen receptor (tibolone) Women's Health / Endocrinology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Schaper & Bruemmer GmbH & Co KG:

Cite this brief

Drug Landscape (2026). Schaper & Bruemmer GmbH & Co KG — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/schaper-bruemmer-gmbh-co-kg. Accessed 2026-05-17.

Related